Asset Details
Do you wish to reserve the book?
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Do you wish to request the book?
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
2019
Overview
This phase 3, randomized trial in China compared the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, with placebo for anemia in patients with CKD who were not undergoing dialysis. Roxadustat was superior to placebo in increasing and maintaining hemoglobin levels.
Publisher
Massachusetts Medical Society
Subject
/ Acidosis - chemically induced
/ Adult
/ Aged
/ Anemia
/ Dialysis
/ Female
/ Glycine - analogs & derivatives
/ Hematinics - adverse effects
/ Hematinics - therapeutic use
/ Hepcidin
/ Humans
/ Hyperkalemia - chemically induced
/ Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors
/ Iron
/ Isoquinolines - adverse effects
/ Isoquinolines - therapeutic use
/ Male
/ Patients
